Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

Blood

Volumn 101, Issue 2, 2003, Pages 703-705

  Hideshima, Teru ^a   Akiyama, Masaharu ^a   Hayashi, Toshiaki ^a   Richardson, Paul ^a   Schlossman, Robert ^a   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; BONE MARROW CELL; CELL ADHESION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PARACRINE SIGNALING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

EID: 0037438374     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-06-1874     Document Type: Article

References (22)

1. Lichtenstein A, Tu Y, Fady C, Vescio R, Berenson J. Interleukin-6 inhibits apoptosis of malignant plasma cells. Cell Immunol. 1995;162:248-255.
2. Ogata A, Chauhan D, Teoh G, et al. Interleukin-6 triggers cell growth via the ras-dependent mitogen-activated protein kinase cascade. J Immunol. 1997;159:2212-2221.
3. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood. 1997;89:227-234.
4. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene. 2001;20:5991-6000.
5. Podar K, Tai YT, Davies FE, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98:428-435.
6. Chauhan D, Uchiyama H, Akbarali Y, et al. Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-κB. Blood. 1996;87:1104-1112.
7. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma. Cancer Res. 2001;61:3071-3076.
8. Gupta D, Treon SP, Shima Y, et al. Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia. 2001;15:1950-1961.
9. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogues overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000;96:2943-2950.
10. Lentzsch S, Rogers MS, LeBlanc R, et al. S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice. Cancer Res. 2002;62:2300-2305.
11. Richardson PG, Berenson J, Irwin D, et al. Phase II trial of PS-341, a novel proteasome inhibitor, alone or in combination with dexamethasone, in patients with multiple myeloma who have relapsed following front-line therapy and are refractory to their most recent therapy [abstract]. Blood. 2001;98:774a.
12. Richardson P, Schlosman R, Weller E, et al. Immunomodulatory derivative of thalidomide CC-5013 overcomes drug resistance and is well toleraied in patients with relapsed multiple myeloma. Blood. 2002;100:3063-3067.
13. De Cesaris P, Starace D, Riccioli A, Padula F, Filippin A. Tumor necrosis factor-α induces interleukin-6 production and integrin ligand expression by distinct transcription pathways. J Biol Chem. 1998;273:7566-7571.
14. Craig R, Larkin A, Mingo AM, et al. p38 MAPK and NF-κB collaborate to induce interleukin-6 gene expression and release. J Biol Chem. 2000;275:23814-23824.
15. Chae HJ, Chae SW, Chin HY, et al. The p38 mitogen-activated protein kinase pathway regulates interleukin-6 synthesis in response to tumor necrosis factor in osteoblasts. Bone. 2001;28:45-53.
16. Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multipe myeloma. J Biol Chem. 2002;277:6639-6647.
17. Hideshima T, Chauhan D, Hayashi T, et al. The biological sequelae of stromal cell-derived factor-1α in multiple myeloma. Mol Cancer Ther. 2002;1:539-544.
18. Uchiyama H, Barut BA, Mohrbacher AF, Chauhan D, Anderson KC. Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates IL-6 secretion. Blood. 1993;82:3712-3720.
19. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor a in the pathogenesis of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-4527.
20. Read MA, Whitley MZ, Gupta S, et al. Tumor necrosis factor α-induced E-selectin expression is activated by the nuclear factor-kappaB and c-JUN N-terminal kinase/p38 mitogen-activated protein kinase pathways. J Biol Chem. 1997;272:2753-2761.
21. Barbin G, Roisin MP, Zalc B. Tumor necrosis factor alpha activates the phosphorylation of ERK, SAPK/JNK, and P38 kinase in primary cultures of neurons. Neurochem Res. 2001;26:107-112.
22. Dankbar B, Padro T, Leo R, et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood. 2000;95:2630-2636.